Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) announced its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($200.00) by $199.94, reports.
Hepion Pharmaceuticals Stock Performance
HEPA stock remained flat at $0.12 during midday trading on Wednesday. 32,939 shares of the company’s stock were exchanged, compared to its average volume of 27,637. The firm has a market capitalization of $1.32 million, a P/E ratio of -0.03 and a beta of 1.52. The firm has a 50 day simple moving average of $0.11 and a two-hundred day simple moving average of $0.07. Hepion Pharmaceuticals has a fifty-two week low of $0.03 and a fifty-two week high of $0.22.
Hepion Pharmaceuticals Company Profile
Hepion Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver diseases. Its research centered on rencofilstat, an investigational oral cyclophilin inhibitor studied for conditions including nonalcoholic steatohepatitis (NASH) and liver fibrosis. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion name in 2019. Its work included clinical development of rencofilstat; the candidate was investigational and had not been approved as a treatment.
Read More
- Five stocks we like better than Hepion Pharmaceuticals
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
